Kag: my understanding is that BOCX uses a "curve fitting" computer application to determine the exact sensitivity/specificity cutoff value after each clinical testing run. this is explained in the 30 page lung cancer data that BOCX published in response to the SEC stuff -- the paper is in the due diligence post that we put together.
the actual cutoff value will somewhat be set by BOCX but also played with by doctors in the field, as they do with PSA. docs will combine common sense, patient history, and the available data.
DISCLAIMER: NEVER ASSUME INFO ON MESSAGE BOARDS TO BE ACCURATE. ALWAYS DO YOUR OWN DUE DILIGENCE. DON'T BUY STOCK BASED ON THIS POST OR ANY OTHER POST. I OWN A LONG POSITION IN THIS STOCK AND THEREFORE I AM BIASED.